## Abstract The purification of Epstein‐Barr virus‐determined nuclear antigen (EBNA) was attempted on the basis of its biochemical and physicochemical properties and its immunological specificity, assayed by the indirect single radial immunodiffusion test and anti‐complement immunofluorescence abso
Differential inducibility of Epstein-Barr virus in cloned, non-producer raji cells
✍ Scribed by Klaus Bister; Naoki Yamamoto; Harald Zur Hausen
- Book ID
- 102863467
- Publisher
- John Wiley and Sons
- Year
- 1979
- Tongue
- French
- Weight
- 819 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Cells of the human lymphoblastoid non‐producer line Raji were cloned in soft agar. Individual colonies were isolated and analyzed for their inducibility of the Epstein‐Barr virus‐associated early antigen (EA). The induction of EA by the tumor promoter TPA varied among the different cell clones. Clones with very high and very low inducibility of the resident Epstein‐Barr virus genome were further analyzed. Constant differences in the inducibility of EA were observed after activation by tumor promoters, 5‐iododeoxyuridine or antibodies to human IgM. Induction of EA synthesis by super‐infection with Epstein‐Barr virus from the P3HR‐1 line, however, did not vary among the clones tested. No differences in expression of the Epstein‐Barr virus‐associated nuclear antigen (EBNA) were noted in cells of clones with high or low susceptibility to EA induction. DNA reassociation kinetics demonstrated that Raji cells with high susceptibility to EA induction contained a significantly higher number of Epstein‐Barr virus genome equivalents per cell than cells with low susceptibility. Treatment of Raji cells with the tumor promoter TPA did not change the ratio of Epstein‐Barr virus‐specific DNA to cellular DNA.
📜 SIMILAR VOLUMES
## Abstract Four steroids and one protease inhibitor were evaluated for their effects on 12‐__O__‐tetradecanoyl phorbol 13‐acetate (TPA)‐induced and Epstein‐Barr virus‐induced early antigens (EBV‐EA) in Raji cells. Continuous treatment with dexamethasone, prednisolone, hydrocortisone and cortisone
## Abstract Gp350, a late Epstein‐Barr‐virus (EBV) glycoprotein expressed on both the envelope of viral particles and EBV‐producing cells, is also the candidate for the development of an anti‐EBV subunit vaccine. This glycoprotein is thought to play an important role in anti‐EBV immunity. However,